Elizabeth Holmes, the founder of the ill-fated blood-testing company Theranos, is the subject of a new documentary titled *You Can See Everything*, which portrays her in the lead-up to her incarceration. Holmes began serving a 135-month sentence in May 2023 after being convicted of fraud, yet she continues to defend her controversial technology.
:max_bytes(150000):strip_icc():format(jpeg)/elizabeth-holmes-now-101526-457aad9757f547d98d4f0704e77f0798.jpg)
The documentary, directed by Nathan Fielder, offers a unique glimpse into Holmes’ life as she prepared for her descent into the Federal Prison Camp Bryan, located in Texas. Over the course of 34 days, viewers witness her ongoing insistence that she did not deceive investors or patients regarding Theranos’ capabilities. Through candid conversations with Fielder, she maintains that her blood-testing technology was functional, which has raised additional eyebrows considering her legal challenges.
In a particularly revealing scene, Holmes pulls the components of her devised blood-testing machine, known as Einstein, from storage. With pride, she explains its functionality, claiming it works by taking a blood sample and communicating with cloud technology to receive chemical instructions necessary for analysis. According to her assertions, the machine would provide test results upon receiving the correct chemicals.
However, Holmes acknowledges a key issue: while the Einstein machine could theoretically work, Theranos lacked the chemistry required to perform all promised tests. Despite this shortcoming, she continues to assert that the machine itself was operational. Fielder, however, points out a critical distinction; the chemistry is fundamental to the overall functionality of the device.
During Holmes’ trial, prosecutors made it a focal point that she was aware of the limitations of the Einstein machine. They presented evidence that it could only carry out a handful of tests, rendering many results not only unreliable but also misleading. Furthermore, testimony revealed that Holmes relied on conventional blood testing machines to deliver results that the Einstein was supposed to provide, a fact she allegedly failed to disclose to investors.
In January 2022, a jury found Holmes guilty of conspiracy to commit wire fraud against investors and three counts of wire fraud, involving investments exceeding £140 million. While she was acquitted on a separate conspiracy charge and additional fraud counts related to patients, the trial revealed distressing accounts from individuals who received erroneous test results. In one notable case, a woman testified about being misinformed that she had tested positive for HIV due to a Theranos test.
In addition to her prison sentence, Holmes is required to pay $452 million in restitution alongside her former partner, Sunny Balwani, who served as Theranos’ Chief Operating Officer. Holmes is slated for transfer to the Austin Transitional Center, a halfway house in Texas, in August 2027, after completing part of her prison term.
Despite her conviction and impending incarceration, Holmes remains a figure of interest in the world of medical technology. Her partner, Billy Evans, is actively pursuing ventures that may lead to a resurgence in the field, launching a new blood-testing company named Haemanthus. While Evans aims to rectify the failures of Theranos, Holmes has found herself prohibited from holding any position in public companies due to a settlement with the U.S. Securities and Exchange Commission.
Holmes’ defence of her technology raises numerous questions about accountability and ethics in the tech industry, particularly in healthcare. Her insistence on the efficacy of the Theranos machines, even in light of overwhelming evidence to the contrary, casts a paradoxical shadow over her legacy. As the world watches her journey through incarceration and potential rehabilitation, the discourse surrounding innovation and integrity in business continues to grow, urging a collective reassessment of the balance between ambition and honesty.
As the documentary unfolds, Holmes’ complex persona makes it clear that her story is far from over. The reactions to her narrative and ongoing developments in the biotechnology sector will undoubtedly fuel conversations about the future of medical innovation and the importance of transparency in business dealings. The impact of her actions is likely to echo through subsequent discussions on ethics and technology, proving that the lessons from the Theranos saga remain pertinent in today’s rapidly evolving digital landscape.